Develops and commercializes prescription drug products for dermatological conditions. Offers a range of non-prescription skincare products under multiple brands. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.7× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Sales run at $15.2M a year. A small number, but proof the product has real buyers.
There is $6.2M in the vault; even if every debt were paid off, $5.9M would remain.
A loss of $66K against $15.2M in annual sales.
The stock sits at $0.56. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.